Among those with T2D, SH is primarily observed in individuals treated with sulfonylureas or insulin therapy (1, 2) and the combined rate of level 2 (<3.0 mmol/L) and level 3 events may be as high as 7.10 events per person-year in individuals treated with basal-only insulin and double that for those employing basal-bolus insulin therapy (3). The gene discussed is INS; the disease is type 2 diabetes mellitus.